Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection.

Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, O'Connor L, Oakley SJ, Pope CF, Wren MW, Shetty NP, Crook DW, Wilcox MH. · 2013

Read Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. by Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, O'Connor L, Oakley SJ, Pope CF, Wren MW, Shetty NP, Crook DW, Wilcox MH. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3822406.txt.

Introduction

Timothy D. Planche leads a team of co-authors in a diagnostic study in The Lancet Infectious Diseases, dated 2013 in the record. They test stool samples for Clostridium difficile, a gut germ that causes severe diarrhea in hospital patients. Labs disagree on the best test, so the team check test results against how patients fare.

Samples came from four United Kingdom labs and were run through two reference methods plus tests for the germ, its toxins, and its toxin genes. One reference method flags people who carry the germ but have no free toxin in stool. Patient outcomes, such as stay length and death within a set window, show which result marks true disease. The study builds a best test path from that proof.

Catalog record

CREATORPlanche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, O'Connor L, Oakley SJ, Pope CF, Wren MW, Shetty NP, Crook DW, Wilcox MH.
YEAR2013
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3822406

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection By Timothy D Planche, Kerrie A Davies, Pietro G Coen, John M Finney, Irene M Monahan, Kirsti A Morris, Lily O'Connor, Sarah J Oakley, Cassie F Pope, Mike W Wren, Nandini P Shetty, Derrick W Crook Published in: The Lancet. Infectious Diseases DOI: 10.1016/S1473-3099(13)70200-7 ABSTRACT Summary Background Diagnosis of Clostridium difficile infection is controversial because of many laboratory methods, compounded by two reference methods. Cytotoxigenic culture detects toxigenic C difficile and gives a positive result more frequently (eg, because of colonisation, which means that individuals can have the bacterium but no free toxin) than does the cytotoxin assay, which detects preformed toxin in faeces. We aimed to validate the reference methods according to clinical outcomes and to derive an optimum laboratory diagnostic algorithm for C difficile infection. Methods In this prospective, multicentre study, we did cytotoxigenic culture and cytotoxin assays on 12 420 faecal samples in four UK laboratories. We also performed tests that represent the three main targets for C difficile detection: bacterium (glutamate dehydrogenase), toxins, or toxin genes. We used routine blood test results, length of hospital stay, and 30-day mortality to clinically validate the reference methods. Data were categorised by reference method result: group 1, cytotoxin assay positive; group 2, cytotoxigenic culture positive and cytotoxin assay negative; and group 3, both reference methods negative. Findings Clinical and reference assay data were available for 6522 inpatient episodes. On univariate analysis, mortality was significantly higher in group 1 than in group 2 (72/435 [16·6%] vs 20/207 [9·7%], p=0·044) and in group 3 (503/5880 [8·6%], p<0·001), but not in group 2 compared with group 3 (p=0·4). A multivariate analysis accounting for potential confounders confirmed the mortality differences between groups 1 and 3 (OR 1·61, 95% CI 1·12–2·31). Multistage algorithms performed better than did standalone assays. Interpretation We noted no increase in mortality when toxigenic C difficile alone was present. Toxin (cytotoxin assay) positivity correlated with clinical outcome, and so this reference method best defines true cases of C difficile infection. A new diagnostic category of potential C difficile excretor (cytotoxigenic culture positive but cytotoxin assay negative) could be used to characterise patients with diarrhoea that is probably not due to C difficile infection, but who can cause cross-infection. Funding Department of Health and Health Protection Agency, UK. INTRODUCTION Clostridium difficile infection is usually health-care associated, is related to antibiotic use, and usually manifests as diarrhoea. The infection causes an estimated 3000 deaths every year in the UK and 15 000–20 000 deaths in the USA,1, 2 with associated case-fatality rates of 6–17%.3, 4, 5, 6 It is associated with the overgrowth of C difficile and the production of toxins A or B, or both, which cause a range of effects, including gut mucosal damage, colitis, and pseudomembranous colitis. Since the features of health-care-associated diarrhoea cannot reliably distinguish C difficile from other causes, laboratory confirmation is essential. However, optimum laboratory diagnosis of C difficile infection remains controversial.7, 8, 9, 10, 11 Two reference methods exist: the cell cytotoxicity assay, which detects neutralisable toxins; and cytotoxigenic culture, which establishes whether cultured C difficile isolates can produce toxin in vitro. Crucially, the reference methods detect different targets, and so cytotoxigenic culture might be regarded as having inadequate specificity,9, 12 or toxin detection as having insufficient sensitivity.9, 13 However, the significance of a positive result with either of these methods is unclear, and in turn hinders the clinical interpretation and validation of diagnostic methods for C difficile infection.12 The availability of many commercial tests with different C difficile targets is both indicative of, and contributes to, uncertainty. The widely available assays are C difficile toxin A and B enzyme immunoassays that detect free toxin in faeces,14, 15 glutamate dehydrogenase tests that detect a common antigen produced by C difficile, and nucleic acid amplification tests that detect toxin genes but not free toxin. The performances of C difficile toxin enzyme immunoassays are inadequate, with positive predictive values less than 50% in settings of low disease prevalence.14, 15, 16 Glutamate dehydrogenase assays have been proposed as the first step in two-stage algorithms for diagnosis of C difficile infection,17, 18, 19, 20 but their low specificity makes them unsuitable as standalone tests. Several toxin gene nucleic acid amplification tests are available, but are also not ideal as standalone tests; they are quite expensive (about five to ten times more expensive than enzyme immunoassay) and the lower 95% CI for sensitivity is roughly 80–85% and that for specificity is about 93%.12 Since available diagnostic assays seem to be inadequate as standalone tests, several two-stage or three-stage algorithms have been proposed.17, 18, 19, 20, 21 However, most studies comparing C difficile tests and algorithms have neither assessed each potential target nor used both reference methods, and have relied on low sample numbers (usually from a single centre), leading to unacceptably wide confidence intervals.17, 18, 19, 21 A recent survey of UK diagnostic laboratories drew attention to the absence of consensus about the optimum algorithm when it showed that more than 25 different algorithms for C difficile infection are now in use.22 Imprecise diagnosis has implications for infection control practice, patient management, and performance management of institutions.7, 12 The situation is exacerbated because health-care-associated diarrhoea often results from causes other than C difficile infection, including other infections (eg, norovirus), antibiotics, laxatives, or surgery. To address these shortcomings, we undertook a large observational diagnostic study in four routine diagnostic laboratories, in which we used routinely submitted diarrhoeal faecal samples. We aimed to clinically interpret the reference methods for C difficile infection, and to assess C difficile test performance with sufficient accuracy to compare single assays and establish the best possible algorithm for the laboratory diagnosis of C difficile infection. METHODS Study design We did this study in four UK hospital diagnostic laboratories serving Leeds Teaching Hospitals NHS Trust, St George's Healthcare NHS Trust, Oxford University Hospitals NHS Trust, and University College London Hospitals NHS Foundation Trust, and their respective communities. The four study hospitals are major teaching hospitals, each covering the following specialties: general medicine and surgery, elderly patients, children, renal, transplant, and oncology. The average testing rate in these hospitals was 142·7 tests per 10 000 patient bed days (range 105–156 per 10 000). We did all assays on all specimens during a training phase (October, 2010–April, 2011). We established the optimum algorithm for each reference method and carried it forward to the testing phase (May–September, 2011). We tested samples in the training and testing phases with both reference methods. The study was approved by the National Research Ethics Service (reference number 10/H0715/34). Samples and procedures Faecal samples from both hospital and community patients submitted for routine testing for C difficile were eligible for inclusion. We followed the routine protocol for sample submission and C difficile testing in the UK. We tested all unformed faecal samples (Bristol stool chart types 5–7, not clearly attributable to an underlying disease or treatment) from all hospital patients (aged ≥2 years) and from individuals in the community (aged ≥65 years), irrespective of C difficile or other testing requests. Samples were stored at 2–5°C and analysed

Read the complete text